Recruiting
Phase 1
Phase 2

GGTA1 KO Thymokidney

Sponsor:

United Therapeutics

Code:

NCT07224763

Conditions

ESRD (End-Stage Renal Disease)

Kidney Transplantation

Xenotransplantation

Eligibility Criteria

Sex: All

Age: 40 - 70

Healthy Volunteers: Not accepted

Interventions

GGTA1 KO Thymokidney

Study Details

Brief summary:

The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2).

The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant or for 52 weeks following nephrectomy, if required.

Conditions

ESRD (End-Stage Renal Disease)

Kidney Transplantation

Xenotransplantation

Study ID

NCT07224763

Start date

Nov, 2026

Status verified date

Sep, 2026

Completion date

Nov, 2076

Anticipated

Primary completion date

Nov, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria for all Participants (Groups 1 and 2):

1. Provide voluntarily informed consent to participate in the study and for lifetime follow-up.
2. Have a diagnosis of ESRD at the time of informed consent.
3. Hemodialysis dependent for a minimum of 6 months and has a functioning arterial-venous fistula/graft or permanent catheter at the time of informed consent.
4. 50 to 70 years of age at the time of informed consent, or 40 to <50 years of age with a calculated panel reactive antibody (cPRA) of ≥99.9%.
5. Evidence of thymic involution on chest computed tomography (CT) scan with a thymic region of interest score of ≤1.
6. Live within 3 hours travel time of the xenotransplant center.
7. Female participants must be postmenopausal or permanently sterilized (eg, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy). Male participants must agree to the use of a highly effective method of birth control, if the possibility of conception exists.
8. Negative xeno-crossmatch at Screening and pre-transplant.
9. Estimated Post Transplant Survival Calculator score >20%.(https://optn.transplant.hrsa.gov/data/allocation-calculators/epts-calculator/).
10. Body mass index ≤35 kg/m2.
11. Have completed or have initiated and plan to complete (meningococcal A, C, W, Y and meningococcal B vaccine series only) Centers for Disease Control and Prevention-recommended courses of age- and risk-factor-appropriate vaccinations.
12. Seropositive (immunoglobulin G) for cytomegalovirus and Epstein-Barr virus.

Additional Inclusion Criteria for Group 1:

1\. Ineligible for conventional allogeneic kidney transplantation due to medical reason(s) for any of the following:

1. Ineligible for a living donor transplant.
2. Ineligible for an OPTN kidney transplant waitlist (reason for ineligibility will be collected).
3. Delisted from OPTN kidney transplant waitlist (reason for delisting will be collected).

Additional Inclusion Criteria for Group 2:

1. On an OPTN kidney transplant waitlist (active or inactive status).
2. No approved living kidney donors.
3. More likely to die or go untransplanted within 5 years than receive a kidney transplant as measured by the Kidney Transplant Decision Aid at the time of informed consent (select United States for "Choose your state" field and National average for "Choose your transplant program" field; https://www.srtr.org/tools/kidney-transplant-decision-aid/).

Exclusion Criteria (pertain to all participants in Groups 1 and 2):

1. Need for multiple organ transplants.
2. Severe medical co-morbidities including, but not limited to:

1. Chronic liver disease.
2. Advanced cardiovascular disease.
3. Severe peripheral vascular disease that limits technical ability to transplant the GGTA1 KO Thymokidney.
4. Severe neurologic diseases or conditions that would preclude meaningful recovery or informed consent.
5. Oral steroid-dependent airway disorder or chronic pulmonary disease or requires chronic, intermittent, or continuous supplemental oxygen.
6. Pulmonary hypertension.
7. Uncontrolled diabetes or sequelae of diabetes mellitus including severe non-proliferative diabetic retinopathy.
8. Severe neurogenic bladder that requires intermittent catheterization.
3. ESRD due to hereditary or structural kidney disease.
4. Active or recently treated malignancy at the time of informed consent.
5. Non-renal cause of hematological disorders associated with anemia (eg, thalassemia and sickle disease).
6. Cannot discontinue chronic anticoagulation therapy (low-dose daily aspirin is permissible).
7. History of major psychiatric disorders with psychiatric hospitalization and/or suicidal ideation within 5 years of informed consent.
8. Being treated for active tuberculosis (TB), have received prophylaxis for positive FDA-approved interferon-gamma release assay, or test positive for TB by FDA-approved interferon-gamma release assay test during Screening.
9. Nucleic acid test (NAT) positive for hepatitis B virus and/or hepatitis C virus, hepatitis B surface antibody (anti-HBs) titer <10 mIU/mL unless the participant is determined to be a nonresponder to hepatitis B vaccination (a nonresponder is defined as having an anti-HB titer <10 mIU/mL after having completed both the standard vaccine series and a fourth booster dose and/or second standard vaccine series), and/or positive for human immunodeficiency virus (HIV; HIV-1 and HIV-2 antibody and/or NAT).
10. Not able to independently perform activities of daily life.
11. Have a history of medical noncompliance that may preclude adherence to the demands and requirements of xenotransplantation (eg, history of substance use disorder \[SUD\] within 1 year of informed consent, lack of social support, untreated psychological conditions).

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: GGTA1 KO Thymokidney

Participants will receive GGTA1 KO Thymokidney

Interventions

GGTA1 KO Thymokidney

Porcine kidney containing an intentional genomic alteration and thymic tissue autograft for xenotransplantation

Primary outcome measure

  • Survival Rate of Patients with ESRD Receiving the GGTA1 KO Thymokidney at 24 Weeks Post Transplant [ Time Frame: Day 0 (day of xenotransplantation) to 24 weeks post transplant ]
  • Survival Rate of the GGTA1 KO Thymokidney at 24 Weeks Post Transplant [ Time Frame: Day 0 (day of xenotransplantation) to 24 weeks post transplant ]
  • Survival Time of Participants Receiving the GGTA1 KO Thymokidney [ Time Frame: Day 0 (day of xenotransplantation) until death for any cause, assessed at least every 24 weeks after transplantation while the participant is alive, up to 50 years ]
  • Survival Time of the GGTA1 KO Thymokidney (Overall Survival) [ Time Frame: Day 0 (day of xenotransplantation) until start of chronic dialysis, nephrectomy, or death, whichever occurs first, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years ]
  • Survival Time of the GGTA1 KO Thymokidney (Death-censored Survival) [ Time Frame: Day 0 (day of xenotransplantation) until start of chronic dialysis, nephrectomy, or death, whichever occurs first, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years ]
  • GGTA1 KO Thymokidney Function Post Transplant (Endogenous GFR) [ Time Frame: At 24 weeks post transplant ]
  • GGTA1 KO Thymokidney Function Post Transplant (Exogenous GFR) [ Time Frame: At 24 weeks post transplant ]
  • GGTA1 KO Thymokidney Function Post Transplant (Proliferative Responsiveness) [ Time Frame: At 24 weeks post transplant ]
  • Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by EuroQol 5-Dimension 5-Level (EQ-5D-5L) [ Time Frame: Baseline to 24 weeks post transplant ]
  • Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by Standardized Outcomes in Nephrology Life Participant (SONG-LP) [ Time Frame: Baseline to 24 weeks post transplant ]
  • Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by Kidney Transplant Questionnaire (KTQ) [ Time Frame: Baseline to 24 weeks post transplant ]
  • Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by Patient Global Impression of Change (PGI-C) [ Time Frame: At 24 weeks post transplant ]
  • Incidence of Treatment-Emergent Adverse Events (Safety of the GGTA1 KO Thymokidney) [ Time Frame: Baseline until last visit, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years, or for 1 year after nephrectomy if required ]
  • Incidence of Proteinuria [ Time Frame: Day 0 (day of xenotransplantation) until last visit, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years, or for 1 year after nephrectomy if required ]
  • Incidence of Zoonotic Infection [ Time Frame: Day 0 (day of xenotransplantation) until last visit, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years, or for 1 year after nephrectomy if required ]
  • Incidence of Opportunistic Infection [ Time Frame: Day 0 (day of xenotransplantation) until last visit, assessed at least every 24 weeks after transplantation while the participant is alive and the thymokidney is functional, up to 50 years, or for 1 year after nephrectomy if required ]

Central Contacts and Locations

Central contacts

United Therapeutics Global Medical Information

919-485-8350clinicaltrials@unither.com

Locations

New York University Langone Health

Recruiting

New York, New York, United States, 10016

Contacts

Principal Investigator:

Robert A Montgomery, MD, DPhil

More Information

Sponsor

United Therapeutics

Last update posted

Sep 9, 2026

Last verified

Sep, 2026

Keywords

  • End-stage renal disease
  • ESRD
  • Xenotransplantation
  • GGTA1 KO Thymokidney

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by United Therapeutics on 2026-09-09.